Skriba App Privacy Policy

Last Updated: January 24, 2026

RXME ("we," "our," or "us"), managed by RXME in Paarl, Western Cape, South Africa, is committed to protecting your privacy. This Privacy Policy explains how we collect, use, disclose, and safeguard your personal information when you use our mobile app (the "App") and participate in our patient care program for weight management and prescriptions.

This policy applies to data collected through the App and our services. It complies with South Africa's Protection of Personal Information Act (POPIA) and other applicable laws.

If you have questions, contact us at privacy@rxme.online.

1. Information We Collect
We collect information necessary to provide healthcare services, prescriptions, and support:

- Personal Information: Name, email, phone number, date of birth, delivery address, payment details.
- Health and Sensitive Information: BMI, medical history, weight-related conditions, prescriptions (e.g., compounded Semaglutide or Tirzepatide), treatment progress.
- Device and Usage Data: IP address, device type, app logs, location (if enabled for delivery).
- Other: Communications and feedback.

We collect this when you provide it (e.g., sign-up, consultations) or automatically (e.g., logs). We do not collect data from children under 12 without guardian consent.

2. How We Use Your Information
- To diagnose, prescribe, dispense medications, and manage treatment.
- To operate the RxMe patient support program (monitoring, reminders).
- To process payments, deliveries, and communications.
- To improve the App and ensure security.
- To comply with legal requirements (e.g., SAPC, SAHPRA, POPIA).

Health data is used only for treatment with your consent (see separate informed consent form).

3. Sharing Your Information
We share data only as needed:
- With our healthcare team (doctors, nurses, dieticians) for care.
- With licensed pharmacies for compounding/dispensing.
- With couriers for delivery.
- With service providers (e.g., payment processors) under confidentiality agreements.
- As required by law (e.g., regulatory authorities).

We do not sell data or share for marketing without consent.

4. Data Security
We use encryption (e.g., HTTPS), access controls, and secure servers. We comply with POPIA. No system is fully secure.

5. Data Retention and Deletion
We keep data as needed for treatment and legal compliance (e.g., medical records up to 7 years). Request deletion via https://app.admin.rxme.online/policy/delete or email privacy@rxme.online. We will delete/anonymize promptly, subject to legal retention.

6. Your Rights (Under POPIA)
- Access, correction, deletion, objection to processing.
- Withdraw consent (may affect treatment).
Contact us; we respond within 30 days.

For EEA/UK users: Additional GDPR rights apply.

7. Children's Privacy
Not intended for under 12. Ages 12-18 require guardian consent.

8. Changes to This Policy
Updates posted here; continued use means acceptance.

9. Contact Us
Email: privacy@rxme.online
Address: RXME, Paarl, Western Cape, South Africa.



---------------


1. RxME Practive Privacy Policy statement: RXME, Managed by RXME

Last Updated: January 24, 2026

1.1 The practice of RXME (“the Practice”) make use of the clinical experience of our multidisciplinary healthcare team, consisting of doctors, a psychiatrist, dieticians and registered nurses, which we integrate with the best available external clinical experience obtained through systematic research, to diagnose your health condition and prescribe appropriate treatment.

1.2 Our practice is licensed to dispense medicine to our own patients, with the right to sub-contract the compounding thereof to a specialist compounding pharmacy in terms of the prescription issued by us.

1.3 In doing so the Practice prescribes the use of specially formulated medication, compounded for you on a patient specific basis, making use of active ingredients that are used in other medicines registered in South Africa.

1.4 This medication is compounded in a retail pharmacy registered with the SAPC; however it has not been tested to prove that it works the same way in the human body as the registered medication. This means while strict quality standards are followed in compounding the medication, the Practice cannot guarantee it will have the same effect as the registered medicine.

1.5 We are however able to warrant the quality, and safety of the medicines prescribed and compounded for, and dispensed to you by our practice; provided it is stored and used strictly in accordance with our written instructions.

2. Patient Care Programme
As part of our holistic approach to healthcare, we, in conjunction with our practice management team RxMe, also provided you with a continued and effective monitoring and patient support programme, free of charge, the details of which will be provided to you in writing, when you enter our patient treatment programme (“the RxMe patient support programme”).

3. Eligibility for Treatment and Your fundamental Rights
3.1 You as patient, or as the lawful representative of the patient, have the following constitutional rights in terms of our Constitution (Section 27(1)(a)), read with the National Patients’ Charter:

3.1.1 Participation in Decision Making – the right to participate in decision-making on matters affecting your own or the patient’s health;

3.1.2 Choice of Health Services – the right to choose a particular health care provider or a particular treatment;

3.1.3 Informed Consent – the right to be given full and accurate information about the nature of your, or the patient’s health condition, and the proposed preventative and/or remedial treatment to be prescribed, the risks and benefits, and the costs thereof.

3.2 Patients with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater and a weight-related medical condition may be considered for treatment with GLP-1 analogues. For patients with a BMI below these thresholds, using GLP-1 analogues will be regarded as off-label and only after a thorough evaluation of the risk-to- benefit ratio.

Page 1 of 3 3.3 GLP-1 receptor agonists may be used for adolescents from the age of 12 to18 years meeting the following criteria:

3.3.1 BMI ≥ 95th percentile or BMI ≥ 85th percentile with weight-related comorbidities;

3.3.2 Clinical diagnosis of Type 2 Diabetes, including fasting plasma glucose ≥7 mmol/L or abnormal oral glucose tolerance test results;

3.3.3 Adolescents receiving treatment in this age group require the written informed consent of their legal guardian(s), along with their assent, acknowledging that the decision to proceed with treatment is made in consultation with a qualified healthcare provider and in the best interests of the adolescent’s health and well- being, in accordance with Section 129 of the Children’s Act (38 of 2005).

4. Acknowledgements

4.1 I was informed and accept that use of the medicine containing Semaglutide and Tirzepatide prescribed compounded and dispensed to me, or the patient for whom I act as care giver, may cause the following side- effects, when administering the medicine: headaches, dizziness, nausea, muscle and other body pains, tiredness, diarrhoea, heart palpitations and/or abdominal pains.

4.2 I have been made aware, before consultation, diagnosis, prescription and dispensing of any medication containing Semaglutide and Tirzepatide, and before administration and/or self-administration of such medicines, of the following contraindications:

4.2.1 Absolute contra-indications: Family history or personal history of medullary thyroid carcinoma, recent pancreatitis and multiple endocrine neoplasm type 2, active cancer or current chemotherapy treatment, pregnancy, breastfeeding, and known hypersensitivity;

4.2.2 Relative contra-indications and special precautions: Chronic liver and kidney diseases and Type 1 Diabetes Mellitus.

4.2.3 I confirm that I shall be solely responsible for any failure to disclose any medical condition prior to receiving medicine containing Semaglutide or Tirzepatide for administration, which may result in adverse events or results, and/or physically damage, or otherwise.

4.3 In signing this consent, I declare that I have been informed:

4.3.1 That if chronic overweight, and obesity is not treated timeously and effectively, it can progress to type 2 diabetes (T2D) and cardiovascular disease;

4.3.2 that Semaglutide and Tirzepatide:

4.3.2.1 are amino acids known as agonist receptors, that mimic glucon-like peptide-1 (GLP-1), and glucose dependent insulinotropic polypeptide (GIP), which reduce appetite and food intake in humans;

4.3.2.2 are the active ingredients of two other medicines registered in South Africa in terms of the Medicines And Related Substances Act 1965 (No 101 of 1965) (“the Medicines Act”), which are commercially available;

4.3.2.3 that the safety and efficacy of the use of both Semaglutide and Tirzepatide in the treatment of chronic weight management have been proven in several clinical trials, and the results thereof have been accepted by both the Food and Drug Administration of the United States of America (“the FDA”) and the European Medicines Agency (“EMA”), which are regulatory authorities acknowledged by the South African Health Products Regulatory Authority (“SAHPRA”);

4.4 I have for purposes of clause 4.3.2 been provided with access to the following articles:

4.4.1 Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss;

4.4.2 FDA Approves New Medication for Chronic Weight Management;

4.4.3 FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014;

4.4.4 Mounjaro: Tirzepatide Overview;

4.4.5 Wegovy: Semaglutide Overview;

4.4.6 Ozempic: Semaglutide Overview.

4.5 I have also been informed that an injectable combination of Semaglutide and Tirzepatide (“the ST combination”) prescribed by the practice contains the same active ingredients as the registered medicines, and is safe for the treatment of chronic weight management, with the limited initial side effects listed above.

4.6 I understand that informed patient consent is required to prescribe the ST combination for treatment or intervention for chronic weight management or obesity.

4.7 I confirm that as a result of the foregoing I am in a position to make an informed decision on whether to accept and administer the ST combination as part of my prescribed treatment by RXME;

5. Appointment
5.1 I exercise my fundamental right to appoint the Practice to make a differential diagnosis of my medical conditions, and if necessary and clinically indicated, to prescribe, and have compounded and dispensed on my behalf through their practice, the ST combination on the basis of their policy statement recorded in clause 1.1, and undertake to participate in the RxMe patient support programme.

5.2 I authorize delivery of my, or the patient’s prescribed and dispensed medicine by means of the courier, contracted to the Practice, who can warrant the transportation of the medicine under the required conditions.

6. Indemnity
6.1 I indemnify the Practice against any claim by me, or instituted on behalf of the patient, arising out of the storage and use of ST compounded combination dispensed to me or the patient in terms of a prescription issued by the Practice, other than in terms of the prescription and the written instructions of the Practice, and my, or the patient’s failure to participate in the RxMe patient support programme.

6.2 I confirm that I give the indemnity in clause 6.1 voluntarily, and after I have fully consulted on the safety, efficacy and quality of the ST compounded combination with a doctor who is part of the Practice.

6.3 I hereby indemnify and hold the Practice harmless from any claim, for damages, any legal costs of legal actions of any nature by myself or any one on my behalf, as a result of:

6.3.1 Any incorrect use or dosage of the prescribed medicine dispensed to me, in my personal capacity or as care give of the patient, during self-administration of the treatment and medicine;

6.3.2 failure to disclose ant contra-indicated conditions referred to above prior to receipt or administration of the prescribed medicine dispensed to me by the Practice;

6.3.3 the use of any medicine containing Semaglutide or Tirzepatide other than the registered medicine, or the medicine prescribed , compounded and dispensed to me by the Practice